Cover Image
市場調查報告書

全球肽抗生素市場、臨床實驗平台考察

Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023

出版商 KuicK Research 商品編碼 531428
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肽抗生素市場、臨床實驗平台考察 Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023
出版日期: 2017年07月21日 內容資訊: 英文 140 Pages
簡介

本報告提供全球肽抗生素市場相關調查分析,開發與商業化相關的臨床/非臨床參數相關的系統性資訊。

第1章 肽抗生素:新時代的抗生素

  • 簡介
  • 系統化

第2章 肽抗生素的機制和生產

  • 細菌表面的方法
  • 生成流程

第3章 人抗菌肽的鑑定

  • 人防禦素
  • 人抗菌肽
  • 抗菌性神經肽

第4章 癌症治療的肽抗生素的作用

  • 簡介
  • 癌症治療的抗菌肽的機制

第5章 抗癌症肽的類別化

  • α螺旋
  • β片

第6章 已通過核準的肽抗生素

  • Bacitracin
  • Viomycin

第7章 肽抗生素的市場分析

  • 抗菌藥市場概要
  • 全球抗菌肽市場

第8章 抗菌肽的市場動態

  • 有利的參數
  • 課題

第9章 肽抗生素市場、醫藥品開發的未來發展預測

第10章 全球肽抗生素的臨床實驗平台概要

  • 各國
  • 各適應症
  • 各作用機制
  • 各處方
  • 各通知途徑

第11章 全球肽抗生素的臨床實驗平台:各企業、各適應症、各相位

  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第二階段
  • 第三階段
  • 登記前

第12章 已上市的肽抗生素臨床、專利分析

  • Telavancin (Arbelic & Vibativ)
  • Dalbavancin (Dalvance & Xydalba)
  • Daptomycin Intravenous (Cubicin)
  • Oritavancin (Nuvocid & ORBACTIV)
  • Teicoplanin (Targocid)
  • Vancomycin (Vancomycin hydrochloride)

第13章 競爭情形

  • AMP Therapeutics
  • Eli Lilly
  • GlaxoSmithKline
  • Hospira
  • Kasten
  • Madam Therapeutics
  • Novartis
  • Pacgen Life Science Corporation
  • Pfizer
  • Phosphagenics
  • Savara Pharmaceuticals
  • Theravance
  • Vicuron Pharmaceuticals
目錄

“Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.

Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.

US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.

FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have .These have altogether been the major driving factors in the development of peptide antibiotics.

With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.

Table of Contents

1. Peptide Antibiotics - A New Era for Antibiotics

  • 1.1. Introduction
  • 1.2. Systemization of Peptide Antibiotics & Drugs
    • 1.2.1. Non-Ribosomally Synthesized Peptide Antibiotics
    • 1.2.2. Ribosomal Synthesized Peptide Antibiotics

2. Mechanism & Production of Peptide Antibiotics

  • 2.1. Approach of Peptide Antibiotics on Bacterial Surface
  • 2.2. Creational Process of Peptide Antibiotics

3. Identification of Human Antimicrobial Peptides

  • 3.1. Human Defensins
  • 3.2. Human Cathelicidins
  • 3.3. Antimicrobial Neuropeptides

4. Portrayal of Peptide Antibiotics in Cancer Treatment

  • 4.1. Introduction
  • 4.2. Mechanism of Antimicrobial Peptides in Cancer Treatment

5. Categorization of Anticancer Peptides

  • 5.1. Alpha-Helical Anticancer Peptides
  • 5.2. Beta-Sheet Anticancer Peptides

6. Approved Peptide Antibiotics

  • 6.1. Bacitracin
  • 6.2. Viomycin

7. Market Analysis of Peptide Antibiotics

  • 7.1. Introduction to Antibacterial Drug Market
  • 7.2. Global Antimicrobial Peptide Market

8. Market Dynamics of Antimicrobial Peptides

  • 8.1. Favorable Parameters
  • 8.2. Challenges

9. Future Perspective of Peptide Antibiotics Market & Drug Development

10. Global Peptide Antibiotics Clinical Pipeline Overview

  • 10.1. By Country
  • 10.2. By Indication
  • 10.3. By Mode of Action
  • 10.4. By Formulation
  • 10.5. By Delivery Route

11. Global Peptide Antibiotics Clinical Pipeline by Company, Indication & Phase

  • 11.1. Research
  • 11.2. Preclinical
  • 11.3. Clinical
  • 11.4. Phase-I
  • 11.5. Phase-II
  • 11.6. Phase-III
  • 11.7. Preregistration

12. Marketed Peptide Antibiotics Clinical & Patent Analysis

  • 12.1. Telavancin (Arbelic & Vibativ)
  • 12.2. Dalbavancin (Dalvance & Xydalba)
  • 12.3. Daptomycin Intravenous (Cubicin)
  • 12.4. Oritavancin (Nuvocid & ORBACTIV)
  • 12.5. Teicoplanin (Targocid)
  • 12.6. Vancomycin (Vancomycin hydrochloride)

13. Competitive Landscape

  • 13.1. AMP Therapeutics
  • 13.2. Eli Lilly
  • 13.3. GlaxoSmithKline
  • 13.4. Hospira
  • 13.5. Kasten
  • 13.6. Madam Therapeutics
  • 13.7. Novartis
  • 13.8. Pacgen Life Science Corporation
  • 13.9. Pfizer
  • 13.10. Phosphagenics
  • 13.11. Savara Pharmaceuticals
  • 13.12. Theravance
  • 13.13. Vicuron Pharmaceuticals

List of Tables

  • Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides
  • Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets

List of Figures

  • Figure 1-1: Structure of Some Important Peptide Antibiotics
  • Figure 1-2: Classification & Characterization of Peptide Antibiotics
  • Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth
  • Figure 2-2: Chemical Structure of Teixobactin
  • Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin
  • Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes
  • Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens
  • Figure 4-1: Angiogenesis Inhibition Mechanism of Action
  • Figure 6-1: Bacitracin - Mechanism of Action
  • Figure 7-1: Global - Antibacterial Drug Market (US$ Billion), 2016-2023
  • Figure 7-2: Usage of Therapeutic Peptides & Proteins in Different Disorders (%)
  • Figure 7-3: Global - Peptide Drug Market (US$ Billion), 2016-2023
  • Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration
  • Figure 7-5: Global - Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 7-6: Global - Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide
  • Figure 8-2: Challenges to Antimicrobial Peptide Market Growth
  • Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides
  • Figure 10-1: Global - Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023
  • Figure 10-2: Global - Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023
  • Figure 10-3: Global - Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023
  • Figure 10-4: Global - Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023
  • Figure 10-5: Global - Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023
Back to Top